Our publication on effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus (T2DM) is published today [1].
We report the results of the MID-Frail randomised trial that assessed whether a multimodal intervention in pre-frail and frail older people with T2DM leads to an improvement in physical performance measured at 12 months at an individual level. We evaluated whether this multimodal approach would lead to improvements in a range of relevant secondary outcomes, whether the intervention could be delivered in both primary and secondary settings without excess difficulty, and whether the intervention was cost-effective in this population.
After 12 months, intervention procedures participants had mean SPPB scores 0.85 points higher than those in the usual care group (95% CI, 0.44 to 1.26, P < 0.0001). Dropouts were higher in frail participants and in the intervention group, but significant differences in Short
Physical Performance Battery scores between treatment groups remained consistent after sensitivity analysis. Estimates suggest a mean saving following intervention of 428.02 EUR (2016) per patient per year, with incremental cost-effectiveness ratio analysis indicating a consistent benefit of the described health care intervention over usual care. No statistically significant differences between groups were detected in any of the other secondary outcomes.
In conclusion, we have demonstrated that a 12-month structured multimodal intervention programme across several clinical settings in different European countries leads to a clinically relevant and cost-effective improvement in the functional status of older frail and pre-frail participants with type 2 diabetes mellitus.
References
ive years ago I was lucky enough to be involved in a project that resulted in publications
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
Finding the best vehicle in which to publish your research findings is a perennial challenge.
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Since 2013 we have been sharing our understanding on key issues with friends and clients via our Insider’s Insights.
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
